April 2, 2026
Why Does the Future of Genetic Medicines Rely on LNP Targeting Strategies? Read What Experts Have to Say
Active targeting via site-specific ligand attachment, including DARPin conjugation, enables high-affinity cell recognition and has shown ~90% mRNA expression in human CD8⁺ T cells, supporting in-vivo CAR-T concepts.